• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

水不溶性药物玻璃态与晶态溶解度优势的比较评估。

A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.

作者信息

Chawla Garima, Bansal Arvind K

机构信息

Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, Phase X, S.A.S. Nagar, Punjab 160062, India.

出版信息

Eur J Pharm Sci. 2007 Sep;32(1):45-57. doi: 10.1016/j.ejps.2007.05.111. Epub 2007 Jun 2.

DOI:10.1016/j.ejps.2007.05.111
PMID:17618092
Abstract

The objective of the present study was to generate and characterize the glassy state of Irbesartan (IBS), with a view to exploit the solubility advantage from disordered high energy system. The major reason for limited solubility benefit from amorphous systems is their devitrification, on exposure to primarily aqueous dissolution medium. IBS is a lipophilic molecule and exhibits poor aqueous solubility and incomplete dissolution. IBS was found to be a good glass former (with glass transition/melting temperature >0.7), non-hygroscopic in nature and showed reasonable solid-state stability. The present work places particular emphasis on studying the influence of various dissolution environments on the devitrification of amorphous system. It was noted that IBS forms a relatively 'stable' glassy system with a 2.5-fold increase in aqueous solubility and a higher intrinsic dissolution rate (IDR). The dissolution behavior showed pH dependency and about eight-fold solubility advantage was obtained from amorphous system at pH 3. Both the crystalline and amorphous forms exhibited appreciably high solubility in HCl and HCl strength was found to significantly influence the solubility of crystalline form. Amorphous IBS showed reduced devitrification in HCl, as against water, thus highlighting the effect of dissolution environment on devitrification kinetics. Statistical and mathematical analyses were performed to compare the solubility advantage obtained using amorphous IBS vis-à-vis the crystalline counterpart.

摘要

本研究的目的是制备并表征厄贝沙坦(IBS)的玻璃态,以期利用无序高能体系的溶解度优势。非晶态体系溶解度提升有限的主要原因是其在主要为水性的溶解介质中会发生析晶。IBS是一种亲脂性分子,水溶性差且溶解不完全。研究发现IBS是一种良好的玻璃形成体(玻璃化转变温度/熔点>0.7),本质上不吸湿,且具有合理的固态稳定性。本工作特别着重研究各种溶解环境对非晶态体系析晶的影响。值得注意的是,IBS形成了一个相对“稳定”的玻璃态体系,其水溶性提高了2.5倍,固有溶解速率(IDR)更高。溶解行为显示出对pH的依赖性,在pH 3时,非晶态体系的溶解度优势约为8倍。结晶态和非晶态在HCl中均表现出相当高的溶解度,且发现HCl浓度对结晶态的溶解度有显著影响。与水相比,非晶态IBS在HCl中的析晶减少,从而突出了溶解环境对析晶动力学的影响。进行了统计和数学分析,以比较使用非晶态IBS相对于结晶态IBS所获得的溶解度优势。

相似文献

1
A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.水不溶性药物玻璃态与晶态溶解度优势的比较评估。
Eur J Pharm Sci. 2007 Sep;32(1):45-57. doi: 10.1016/j.ejps.2007.05.111. Epub 2007 Jun 2.
2
Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique.通过固体分散技术提高厄贝沙坦的溶解度、溶出速率和生物利用度
Chem Pharm Bull (Tokyo). 2011;59(4):438-41. doi: 10.1248/cpb.59.438.
3
Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.制备无定形呋塞米钠盐可提高溶解度和溶出速率,并导致大鼠口服给药后的 Tmax 更快。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):942-51. doi: 10.1016/j.ejpb.2013.09.002. Epub 2013 Sep 27.
4
Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives.通过聚合物和非聚合物亲水性添加剂改善难溶性药物在固体分散体中的溶出度。
Acta Pharm. 2008 Sep;58(3):257-74. doi: 10.2478/v10007-008-0016-1.
5
Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate.制备稳定的微米级结晶厄贝沙坦颗粒以提高溶解速率。
Drug Dev Ind Pharm. 2011 Nov;37(11):1357-64. doi: 10.3109/03639045.2011.575379. Epub 2011 May 6.
6
Investigation of the dissolution rate and oral bioavailability of atenolol-irbesartan co-amorphous systems.阿替洛尔-厄贝沙坦共无定形系统溶出速率和口服生物利用度的研究。
Int J Pharm. 2024 Nov 15;665:124704. doi: 10.1016/j.ijpharm.2024.124704. Epub 2024 Sep 21.
7
Molecular mobility study of amorphous and crystalline phases of a pharmaceutical product by thermally stimulated current spectrometry.通过热刺激电流光谱法对药品非晶相和晶相的分子流动性研究
J Pharm Sci. 2002 Jun;91(6):1548-60. doi: 10.1002/jps.10146.
8
Effect of counterions on the properties of amorphous atorvastatin salts.抗衡离子对阿托伐他汀无定形盐性质的影响。
Eur J Pharm Sci. 2011 Nov 20;44(4):462-70. doi: 10.1016/j.ejps.2011.08.023. Epub 2011 Sep 1.
9
Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.氨基酸作为低水溶解性药物的共无定形稳定剂——第 1 部分:制备、稳定性和溶出度的提高。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81. doi: 10.1016/j.ejpb.2013.03.014. Epub 2013 Mar 26.
10
Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches.盐酸帕罗西汀水合物形式从无定形状态的生成:热力学和实验预测方法的评估
Int J Pharm. 2015 Mar 15;481(1-2):114-24. doi: 10.1016/j.ijpharm.2014.12.033. Epub 2015 Jan 12.

引用本文的文献

1
Formulation of silymarin binary and ternary solid dispersions: Characterization, simulation study and cell viability assessment against lung cancer cell line.水飞蓟素二元和三元固体分散体的制剂:表征、模拟研究及对肺癌细胞系的细胞活力评估
Heliyon. 2023 Dec 3;10(1):e23221. doi: 10.1016/j.heliyon.2023.e23221. eCollection 2024 Jan 15.
2
How to Improve Solubility and Dissolution of Irbesartan by Fabricating Ternary Solid Dispersions: Optimization and In-Vitro Characterization.通过制备三元固体分散体提高厄贝沙坦的溶解度和溶出度:优化与体外表征
Pharmaceutics. 2022 Oct 23;14(11):2264. doi: 10.3390/pharmaceutics14112264.
3
A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.
一种无分子相互作用的新型药物共非晶体系:改善他达拉非和瑞格列奈的物理化学性质。
RSC Adv. 2020 Jan 2;10(1):565-583. doi: 10.1039/c9ra07149k. eCollection 2019 Dec 20.
4
Understanding the Effect of Energy Density and Formulation Factors on the Printability and Characteristics of SLS Irbesartan Tablets-Application of the Decision Tree Model.了解能量密度和配方因素对SLS厄贝沙坦片可印刷性和特性的影响——决策树模型的应用
Pharmaceutics. 2021 Nov 20;13(11):1969. doi: 10.3390/pharmaceutics13111969.
5
Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits.局部给药的基于γ-环糊精的滴眼液在兔体内的生物分布和药代动力学
Pharmaceuticals (Basel). 2021 May 18;14(5):480. doi: 10.3390/ph14050480.
6
Influence of the p Value of Cinnamic Acid and -Hydroxycinnamic Acid on the Solubility of a Lurasidone Hydrochloride-Based Coamorphous System.肉桂酸和对羟基肉桂酸的p值对盐酸鲁拉西酮基共无定形体系溶解度的影响。
ACS Omega. 2021 Jan 22;6(4):3106-3119. doi: 10.1021/acsomega.0c05510. eCollection 2021 Feb 2.
7
Irbesartan desmotropes: Solid-state characterization, thermodynamic study and dissolution properties.厄贝沙坦旋转异构体:固态表征、热力学研究及溶解特性
J Pharm Anal. 2019 Oct;9(5):339-346. doi: 10.1016/j.jpha.2019.07.001. Epub 2019 Jul 10.
8
Gel Formation Induced Slow Dissolution of Amorphous Indomethacin.凝胶形成诱导无定形吲哚美辛的缓慢溶出。
Pharm Res. 2019 Sep 12;36(11):159. doi: 10.1007/s11095-019-2700-x.
9
Supersaturation Potential of Amorphous Active Pharmaceutical Ingredients after Long-Term Storage.无定形原料药长期储存后的过饱和度潜力。
Molecules. 2019 Jul 27;24(15):2731. doi: 10.3390/molecules24152731.
10
Effects of Temperature and Ionic Strength of Dissolution Medium on the Gelation of Amorphous Lurasidone Hydrochloride.温度和溶解介质离子强度对无定形盐酸鲁拉西酮凝胶化的影响。
Pharm Res. 2019 Mar 26;36(5):72. doi: 10.1007/s11095-019-2611-x.